Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 523303

The Antihypertensive Effect of the GLP-1 Mimetic Exenatide


Baretić, Maja; Pavlić-Renar, Ivana; Aganović, Izet; Koršić, Mirko; Kaštelan, Darko; Giljević, Zlatko; Jelčić, Jozo; Dušek, Tina.
The Antihypertensive Effect of the GLP-1 Mimetic Exenatide // Abstracts of the 5th Central European Meeting on Hypertension ; u: Kidney & blood pressure research 32 / Tesar, Vladimir (ur.).
Basel: Karger AG, 2009. str. 326-326 (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 523303 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The Antihypertensive Effect of the GLP-1 Mimetic Exenatide

Autori
Baretić, Maja ; Pavlić-Renar, Ivana ; Aganović, Izet ; Koršić, Mirko ; Kaštelan, Darko ; Giljević, Zlatko ; Jelčić, Jozo ; Dušek, Tina.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 5th Central European Meeting on Hypertension ; u: Kidney & blood pressure research 32 / Tesar, Vladimir - Basel : Karger AG, 2009, 326-326

Skup
Central European Meeting on Hypertension

Mjesto i datum
Zagreb, Hrvatska, 22.–25.10.2009

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
hypertension; GLP-1; diabetes mellitus

Sažetak
Glucagon-like peptide-1 (GLP 1) is an incretin, a gastrointestinal hormone secreted from the gut after a meal. The positive glucoregulatory properties of GLP 1 are well known: it inhibits glucagon release, delays gastric emptying and augments satiety with the consequence of weight loss. The incretin mimetic exenatide, a pharmacological agent with a structure similar to that of GLP 1, has all the above properties of endogenous GLP 1. We examined 40 patients with type 2 diabetes mellitus unable to achieve adequate glycemic control with sulphonylurea and/or metformin. Patients were without antihypertensive therapy, or on stable one. Exenatide was added to therapy for 52 weeks: 5 mg of exenatide BID for the first 4 weeks, and then till the end of the study 10 mg BID. At the end of the trial, statistically significant mean reduction in both systolic blood pressure −4.65 mmHg ; p = 0.008582) and diastolic blood pressure (−1.48 mmHg ; p = 0.006286) was observed. GLP 1 receptors are found all over the body, as well as in the kidneys. Both GLP 1 and exenatide enhance sodium excretion, and their diuretic properties could explain the lowering of blood pressure. Do we have a drug that influences three elements of the metabolic syndrome: diabetes, obesity, and hypertension?

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Ustanove:
Klinički bolnički centar Zagreb


Citiraj ovu publikaciju:

Baretić, Maja; Pavlić-Renar, Ivana; Aganović, Izet; Koršić, Mirko; Kaštelan, Darko; Giljević, Zlatko; Jelčić, Jozo; Dušek, Tina.
The Antihypertensive Effect of the GLP-1 Mimetic Exenatide // Abstracts of the 5th Central European Meeting on Hypertension ; u: Kidney & blood pressure research 32 / Tesar, Vladimir (ur.).
Basel: Karger AG, 2009. str. 326-326 (poster, međunarodna recenzija, sažetak, znanstveni)
Baretić, M., Pavlić-Renar, I., Aganović, I., Koršić, M., Kaštelan, D., Giljević, Z., Jelčić, J. & Dušek, T. (2009) The Antihypertensive Effect of the GLP-1 Mimetic Exenatide. U: Tesar, V. (ur.)Abstracts of the 5th Central European Meeting on Hypertension ; u: Kidney & blood pressure research 32.
@article{article, editor = {Tesar, V.}, year = {2009}, pages = {326-326}, keywords = {hypertension, GLP-1, diabetes mellitus}, title = {The Antihypertensive Effect of the GLP-1 Mimetic Exenatide}, keyword = {hypertension, GLP-1, diabetes mellitus}, publisher = {Karger AG}, publisherplace = {Zagreb, Hrvatska} }
@article{article, editor = {Tesar, V.}, year = {2009}, pages = {326-326}, keywords = {hypertension, GLP-1, diabetes mellitus}, title = {The Antihypertensive Effect of the GLP-1 Mimetic Exenatide}, keyword = {hypertension, GLP-1, diabetes mellitus}, publisher = {Karger AG}, publisherplace = {Zagreb, Hrvatska} }

Časopis indeksira:


  • Scopus
  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font